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Abstract The human calcitonin (CT) receptor-like receptor
(hCRLR) of the B family of G protein-coupled receptors is N-
glycosylated and associates with receptor-activity-modifying
proteins for functional interaction with CT gene-related peptide
(CGRP) or adrenomedullin (ADM), respectively. Three putative
N-glycosylation sites Asn60, Asn112 and Asn117 are present in the
amino-terminal extracellular domain of the hCRLR. Tunicamy-
cin dose-dependently inhibited the glycosylation of a myc-tagged
hCRLR and in parallel specific [125I]CGRP and -ADM binding.
Similarly, the double mutant myc-hCRLR(N60,112T) exhibited
minimal N-glycosidase F sensitive glycosylation, presumably at
the third Asn117, and the cell surface expression and specific
radioligand binding were impaired. Substitution of the Asn117 by
Thr abolished CGRP and ADM binding in the face of intact
N-glycosylation and cell surface expression. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The initially orphan calcitonin (CT) receptor-like receptor
(CRLR) belongs to the B family of G protein-coupled recep-
tors that includes the CT receptors (CTR) with 60% amino
acid sequence homology and more distantly related receptors
for parathyroid hormone (PTH), PTH-related protein
(PTHrP), secretin and vasoactive intestinal polypeptide
(VIP) [1,2]. Novel receptor-activity-modifying proteins
(RAMP) are required for the functional expression of human
(h) and rat (r) CRLR, both coupled to cAMP production
[3,4]. The three so far identi¢ed RAMP de¢ne the speci¢city
of the CRLR and CTR isotype 2 for adrenomedullin (ADM),
CT gene-related peptide (CGRP), CT and amylin, all belong-
ing to the CT family of peptides [3^5].
The peptides of the CT family exhibit overlapping physio-
logical actions. Common 6- or 7-amino acid ring structures,
linked by disul¢de bonds between cysteine residues, and ami-
dated carboxyl-termini are essential for biological activity [6].
CGRP and ADM, the peptides studied here, are potent vaso-
dilators [7,8].
Mature glycosylation of hCRLR in the presence of RAMP1
and core-glycosylation with RAMP2 were thought to de¢ne
CGRP and ADM recognition [3]. However, co-expression of
rCRLR and RAMP1 or -2 in Drosophila Schneider 2 cells
revealed RAMP-independent and uniform less extensive ma-
ture glycosylation of both the CGRP and ADM receptors,
functionally indistinguishable from those in mammalian cells
[9]. Within the B family of G protein-coupled receptors the
functional relevance of N-linked glycosylation varies among
receptors. The VIP receptor needs minimal N-glycosylation
for correct delivery to the plasma membrane, but high a⁄nity
binding is maintained in solubilised non-glycosylated receptor
homogenates [10]. The secretin receptor and the human CTR,
on the other hand, are readily transported to the cell surface,
but they require N-glycosylation for the interaction with their
ligands [11,12]. Moreover, the non-glycosylated human PTH/
PTHrP receptor of tunicamycin-treated cells is expressed at
the cell surface and remains fully active [13].
Here, cell surface expression of a myc epitope-tagged
hCRLR (myc-hCRLR) and the functional roles of its three
putative N-glycosylation sites within the N-terminal extracel-
lular domain have been analysed through suppression of N-
glycosylation with tunicamycin and site-directed mutagenesis.
Substitution of the two N-terminal Asn by Thr reduced cell
surface delivery and ligand binding. Asn to Thr replacement
in the third N-glycosylation consensus sequence inactivated
the myc-hCRLR, but the cell surface expression was indistin-
guishable from that of the non-modi¢ed myc-hCRLR.
2. Materials and methods
2.1. Materials
Human KCGRP and human amylin were from Bachem AG (Bu-
bendorf, Switzerland), hLCGRP from Peninsula Laboratories (Bel-
mont, CA, USA), and hADM from Peptide Institute (Osaka, Japan).
Human CT was provided by E. Felder (Novartis, Basel, Switzerland).
Na[125I], enhanced chemiluminescence (ECL)1 Western blot detection
reagents and Hybond ECL1 nitrocellulose membranes were from
Amersham International (Little Chalfont, UK), and restriction en-
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zymes from Promega (Madison, WI, USA). Tissue culture supplies
were from Biological Industries (Kibbutz Beit Haemek, Israel), and
Geneticin, LipofectAMINE and OptiMEM medium for transfections
were from Life Technologies (Gaithersburg, MD, USA). Other re-
agents unless indicated were from Sigma (St. Louis, MO, USA) and
Merck (Darmstadt, Germany).
2.2. cDNA and mutagenesis
Constructs for expression of myc-hCRLR, RAMP1 and -2 were
provided by S. Foord (GlaxoWellcome, Stevenage, UK).
Site-directed mutagenesis, replacing asparagine 60, 112 and 117 by
threonine in N-glycosylation consensus sequences of the hCRLR, was
carried out with the Seamless1 Cloning Kit (Stratagene, La Jolla,
CA, USA), according to the manufacturer’s instructions and [14].
Mutations were ACC substitutions in position 2 of corresponding
Asn-encoding triplets within a Bsu36I/PstI restriction fragment coding
for the hCRLR domain that contains the three predicted N-glycosyl-
ation sites. Bsu36I/Eam1104I and Eam1104I/PstI DNA fragments car-
rying the mutations were ampli¢ed with cloned Pfu DNA polymerase
(Stratagene, La Jolla, CA, USA) by polymerase chain reaction (PCR)
for 30 cycles. The products were digested with corresponding restric-
tion enzymes and gel-puri¢ed. Matching fragments were ligated into
Bsu36I/PstI-digested myc-hCRLR yielding myc-hCRLR(N60T),
-(N112T) and -(N117T). A double mutant myc-hCRLR(N60, 112T)
was obtained as follows: NotI/XhoI DNA fragments, including the
coding sequences of myc-hCRLR(N60T) and -(N112T), were digested
with BglII. The DNA fragment NotI/BglII containing mutation
(N60T) and the fragment BglII/XhoI with mutation (N112T) were
cloned into NotI/XhoI-digested pcDNA3 yielding myc-hCRLR(N60,
112T). All the mutations were veri¢ed by sequencing the PCR ampli-
¢ed DNA fragments including the cloning sites in individual pcDNA3
expression constructs in both directions.
2.3. Cell culture, transfection and tunicamycin treatment
SV40 T-antigen transformed human embryonic kidney (TSA) cells
were cultured in Ham’s F12/Dulbecco’s modi¢ed Eagle’s medium
(DMEM; 4.5 g/l glucose) medium (1:1) supplemented with 10% foetal
calf serum and 400 Wg/ml Geneticin. Twenty-four or 48 h before
transient transfection 2.5 or 1U105 TSA cells per cm2, respectively,
were seeded into 24- or 48-well plates coated with 0.1% gelatine. The
cells were transfected for 4 h at 37‡C in 150 Wl OptiMEM medium per
cm2 containing 0.6 Wl LipofectAMINE and 100 ng of indicated re-
ceptor and of RAMP1 or -2 expression constructs or of pcDNA3 to
keep the amount of DNA constant. The transfected cells were kept in
tissue culture medium for 2 days prior to the experiments. Tunicamy-
cin dissolved in dimethyl sulfoxide (DMSO) or DMSO alone were
added where indicated. Tunicamycin- and DMSO-treated cells were
detached with 0.05% EDTA in phosphate-bu¡ered saline (PBS) and
kept in suspension during the experiments.
2.4. Radioligand binding
[125I]-labelled hKCGRP and hADM were prepared as described
[4,15]. Adherent cells in 24- or 48-well plates and 106 or 2U106 tuni-
camycin-treated cells in suspension were incubated with 1700 Bq
[125I]hKCGRP or -ADM in the absence (total binding) or presence
(non-speci¢c binding) of 1 WM non-labelled hKCGRP or hADM in
0.5 ml Ham F12 and DMEM (1:1) supplemented with 0.1% bovine
serum albumin for 2 h at 15‡C. Subsequently, adherent cells were
washed with ligand-free medium, pre-cooled to 15‡C, and lysed with
0.5% sodium dodecyl sulphate (SDS). Cells in suspension were col-
lected by centrifugation at 200Ug for 5 min at 4‡C and the super-
natants were aspirated. The tips of the tubes containing the cell pellets
were cut o¡. Radioactivity in cell lysates and in cell pellets was mea-
sured in a MR 252 Q-counter (Kontron, Zurich, Switzerland). Speci¢c
binding is de¢ned as the di¡erence between total binding and non-
speci¢c binding.
2.5. Western blotting
TSA cells were detached with 0.05% EDTA in PBS and collected by
centrifugation at 200Ug for 5 min at 4‡C. The cells were lysed in 50
mM Tris (pH 7.8), 150 mM NaCl and 1% Nonidet0 P-40 for 30 min
at 4‡C (10 Wl/106 cells), and the lysates cleared by centrifugation at
10 000Ug for 10 min at 4‡C. Protein content was measured with the
Bio-Rad DC Protein Assay. Aliquots of cell lysates, equivalent to
50^100 Wg protein, were treated with 80 mU/Wl N-glycosidase F
(Boehringer-Mannheim, Mannheim, Germany) in 10 mM Tris (pH
7.5), 10 mM EDTA, 1% L-mercaptoethanol, 0.1% SDS and 0.5%
n-octyl L-D-glucopyranoside for 18 h at 37‡C. The reactions were
stopped with protein gel loading bu¡er. Proteins were separated on
a 8% SDS^polyacrylamide gel and electro-transferred to Hybond1
ECL1 nitrocellulose membranes in 14.4 g/l glycine, 3.03 g/l Tris,
20% methanol using a Trans-Blot cell (Bio-Rad Laboratories, Rich-
mond, CA, USA). Myc-tagged receptor proteins were visualised with
horseradish peroxidase (HRP)-labelled monoclonal antibodies to myc
(1:5000; Invitrogen, Carlsbad, CA, USA) with the ECL1 technique.
Chemiluminescence was visualised with a liquid nitrogen-cooled slow
scan CCD camera (AstroCam).
2.6. Enzyme-linked immunoassay for cell surface-localised myc
Transfected TSA cells in 48-well plates were incubated in 75 Wl
Ham F12/DMEM (1:1) medium containing 10% foetal calf serum
and 4 Wg/ml monoclonal HRP-labelled antibodies to myc (Invitrogen)
for 90 min at room temperature. The cells were then washed four
times with 0.5 ml of the same medium without antibodies. The colour
reaction was started with 0.4 ml 100 mM sodium acetate/50 mM
sodium phosphate bu¡er (pH 4.2) containing 1 mg/ml 2,2P-azino-di-
[3-ethylbenz-thiazoline sulfonate (6)] diammonium salt (Boehringer-
Mannheim, Mannheim, Germany) and hydrogen peroxide (1:3500).
The reaction was stopped by adding SDS to a ¢nal concentration of
0.2%. Absorbance of the supernatant was measured at 405 nm with a
Beckman DU68 spectrophotometer.
2.7. Statistical analysis
Di¡erences between mean values of speci¢c binding were analysed
by ANOVA and of percent optical density at 405 nm compared to
myc-hCRLR controls by Student’s t-test. The values for half maximal
inhibitory concentrations (IC50) were calculated by non-linear regres-
sion analysis using FigP 6.0 (Biosoft, Cambridge, UK).
3. Results
3.1. Inhibition of myc-hCRLR N-glycosylation by tunicamycin
results in a dose-dependent loss of speci¢c [125I]hKCGRP
and [125I]hADM binding
A myc epitope on the N-terminus of the hCRLR (myc-
hCRLR) was used to identify the protein on immunoblots
and to estimate cell surface expression. In TSA cells co-ex-
pressing myc-hCRLR and RAMP1 or -2, [125I]hKCGRP and
[125I]hADM binding amounted to 15 and 12% of added tracer
and predominant myc-hCRLR had apparent sizes of 65 and
58 kDa, respectively (Fig. 1). The IC50 of [125I]CGRP and
Table 1
[125I]hKCGRP and -hADM binding inhibition (IC50) to TSA cells co-expressing myc-hCRLR or receptor mutants with RAMP1 or -2
[125I]hKCGRPa IC50 (nM) [125I]hADMb IC50 (nM)
hKCGRP hLCGRP hADM hAmylin hCT hKCGRP hLCGRP hADM hAmylin hCT
myc-hCRLR 2.2 þ 0.8 1.8 þ 1.0 67 þ 23 65 þ 25 s 1000 s 1000 s 1000 9.7 þ 2.4 s 1000 s 1000
myc-hCRLR(N60T) 5.7 þ 2.9 2.2 þ 0.9 45 þ 22 106 þ 35 s 1000 s 1000 s 1000 33 þ 5 s 1000 s 1000
myc-hCRLR(N112T) 10.7 þ 5.5 1.4 þ 0.8 49 þ 20 78 þ 35 s 1000 s 1000 s 1000 94 þ 14 s 1000 s 1000
Results of IC50 are means þ S.E.M. of at least three independent experiments.
aTSA cells co-transfected with RAMP1.
bTSA cells co-transfected with RAMP2.
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-ADM receptor binding of the myc-hCRLR and the EC50 of
cAMP accumulation with hKCGRP and ADM were those of
the non-myc-tagged receptor (not shown). Tunicamycin dose-
dependently reduced [125I]hKCGRP and [125I]hADM binding
to those observed in the presence of the corresponding non-
labelled peptides at 1037 M or in non-transfected cells de¢ned
as non-speci¢c binding (not shown). In parallel to the loss of
radioligand binding the sizes of the 65 and 58 kDa glycosy-
lated myc-hCRLR were decreased to a protein doublet also
observed for N-glycosidase F-treated myc-hCRLR and con-
sistent in size with the calculated molecular weight of the myc-
hCRLR protein backbone. Incomplete denaturation, e.g. re-
duction of presumed disul¢de bonds between cysteine residues
by L-mercaptoethanol, may explain the migration of deglyco-
sylated myc-hCRLR as a protein doublet. Two intermediate
size myc-hCRLR components in cells co-expressing RAMP1
were also gradually reduced at tunicamycin concentrations of
between 0.2 and 1.6 Wg/ml. Thus, RAMP1 or -2 dependent
expression of myc-hCRLR as CGRP- or ADM receptors re-
quires N-glycosylation.
3.2. N-Glycosylation of Asn60 and/or Asn112 are required for
myc-hCRLR cell surface expression
The hCRLR has three Asn-X-Thr consensus N-glycosyla-
tion sites in the N-terminal extracellular domain. With Asn to
Thr site-directed mutagenesis, myc-hCRLR(N60T), -(N112T),
-(N117T) and the double mutant myc-hCRLR(N60, 112T)
were obtained. Myc-hCRLR and the mutant receptors were
expressed in TSA cells in the absence and presence of RAMP1
or -2.
In TSA cells co-expressing myc-hCRLR or individual
N-glycosylation site mutants together with RAMP1 or -2,
myc-epitope cell surface presentation was used as a measure of plasma membrane localisation (Fig. 2). HRP-labelled myc-
antibodies detected myc-hCRLR and all single-site mutant
receptors at comparable levels at the cell surface. Di¡erent
from the single-site mutant receptors, cell surface localisation
of the double mutant myc-hCRLR(N60, 112T) in the presence
of the RAMP was lowered to between 40 and 50% of the non-
modi¢ed myc-hCRLR. The expression levels of myc-hCRLR
and the mutants, as revealed by Western blot analysis of cell
extracts, were comparable (Fig. 3).
3.3. [125I]hKCGRP and -ADM recognition by myc-hCRLR,
-(N60T), -(N112T), -(N60, 112T) and -(N117T)
In cells expressing myc-hCRLR or the glycosylation mu-
tants (N60T) and (N112T), speci¢c binding of [125I]hK-
CGRP and -ADM was maintained in the presence of the
corresponding RAMP (Fig. 2). The IC50 of hK- and LCGRP,
hADM and human amylin of [125I]hKCGRP and -ADM bind-
ing re£ected the a⁄nities of the expressed receptors (Table 1).
Binding inhibition of [125I]hKCGRP by the non-labelled pep-
tides in cells expressing myc-hCRLR and the (N60T) and
(N112T) mutants was similar. With [125I]hADM, myc-
hCRLR(N60T) and -(N112T) exhibited a 3- and 10-fold high-
er IC50 of hADM as compared to the non-modi¢ed myc-
hCRLR. Di¡erent from the two (N60T) and (N112T) sin-
gle-site mutant receptors speci¢c [125I]hKCGRP and -ADM
binding to the double-mutant (N60, 112T) was below 5% of
the added tracers.
In cells expressing myc-hCRLR(N117T) together with the
corresponding RAMP speci¢c [125I]hKCGRP and [125I]hADM
binding was below 4% of the added tracers. Up to 1037 M
Fig. 1. Radioligand binding and Western blot analysis of myc-
hCRLR expressed in tunicamycin-treated TSA cells. The cells were
co-transfected with myc-hCRLR and RAMP1 (A, C) or -2 (B, D)
expression constructs in the absence (0) and presence of increasing
concentrations of tunicamycin. Open bars in (A) and (B) indicate
total binding. Non-speci¢c [125I]hKCGRP or [125I]hADM binding in
the presence of 1 WM non-labelled hKCGRP or 0.1 WM non-labelled
hADM was 3.0 and 3.8 Bq/105cells, respectively (not shown). Pro-
teins in cell extracts treated with tunicamycin or with N-glycosidase
F (F) were separated by 8% SDS^PAGE. Myc-hCRLR on immuno-
blots (C, D) was visualised by ECL1. Arrows indicate the positions
of protein size markers. Representative experiment carried out three
times.
Fig. 2. Cell surface expression and speci¢c radioligand binding of
the myc-hCRLR and the mutant receptors. TSA cells were transi-
ently transfected with the indicated combinations of receptors and
RAMP1 (A, C) or -2 (B, D) expression constructs. A and B: HRP-
labelled myc-antibody binding, normalised to that of TSA cells co-
expressing myc-hCRLR and RAMP1 (A) or -2 (B). C and D: Spe-
ci¢c radioligand binding. The results are means þ S.E.M. of four in-
dependent experiments. Statistically signi¢cant di¡erences (P6 0.02)
between means of percent myc-antibody binding and speci¢c radioli-
gand binding compared to the myc-hCRLR/RAMP1 or -2 are indi-
cated with an asterisk.
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hKCGRP and hADM failed to stimulate cAMP production in
COS-7, TSA and human embryonic kidney 293 cells co-ex-
pressing myc-hCRLR(N117T) and RAMP1 or -2 (not
shown).
3.4. Western blot analysis of myc-hCRLR and -(N60T),
-(N112T), -(N60, 112T) and -(N117T) in TSA cells
N-Glycosylation of myc-hCRLR and of the mutant recep-
tors was analysed on Western blots through estimation of
relative size di¡erences of receptors before and after N-glyco-
sidase F treatment of cell extracts (Fig. 3). Myc-hCRLR had
an apparent size of 55 to 58 kDa in the absence of the RAMP.
The size increased by approximately 10 kDa when RAMP1
was co-expressed, but was not a¡ected by RAMP2. N-Glyco-
sidase F treatment reduced the size of myc-hCRLR indepen-
dent of co-expressed RAMP to a protein doublet of approx-
imately 45 kDa also observed in the tunicamycin-treated cells.
In the absence of the RAMP the three mutants myc-
hCRLR(N60T), -(N112T) and -(N117T) were smaller than
the non-modi¢ed myc-hCRLR. This size remained unchanged
when RAMP2 was co-expressed and it was also reduced by
N-glycosidase F to that of deglycosylated myc-hCRLR. The
size of myc-hCRLR(N112T) was unaltered when RAMP1 was
co-expressed. A minor fraction of myc-hCRLR(N60T) was
further glycosylated when co-expressed with RAMP1, but
the maximal size was lower than that of the myc-hCRLR.
Glycosylation of myc-hCRLR(N117T) in the presence of
RAMP1 occurred less e⁄ciently but the achieved size was
that of the myc-hCRLR. The reduction of the size of the
double mutant myc-hCRLR(N60, 112T) with N-glycosidase
F treatment indicated minor glycosylation at Asn117 that
was una¡ected by co-expressed RAMP.
4. Discussion
N-Glycosylation of hCRLR was demonstrated by treatment
with N-glycosidase F that reduced its size to that calculated
for the protein backbone [3]. Mature-glycosylation of h- and
rCRLR as a result of the interaction with RAMP1 and core-
glycosylation in the presence of RAMP2 was thought to de-
¢ne the speci¢city of the CRLR for CGRP and ADM ([3],
unpublished). In Drosophila Schneider 2 cells, on the other
hand, rCRLR glycosylation was independent of co-expressed
RAMP1 and -2, but CGRP- and ADM receptor function was
that of rCRLR in mammalian cells [4,9].
In the present study, the functional signi¢cance of N-glyco-
sylation of hCRLR on the cell surface expression and
[125I]CGRP or -ADM binding in the presence of RAMP1 or
-2 was investigated in cells treated with tunicamycin and
through Asn to Thr site-directed mutagenesis of three N-ter-
minal N-glycosylation consensus sites. Treatment with tunica-
mycin reduced the size of myc-hCRLR to that of N-glycosi-
dase F-treated myc-hCRLR, indicating total suppression of
N-glycosylation. In parallel, [125I]CGRP and -ADM binding
were lowered. This is in line with other receptor proteins lo-
cated at the plasma membrane where inhibition of N-glyco-
sylation by tunicamycin impaired their transport to the cell
surface and as a result ligand binding [10,16].
Site-directed mutagenesis of Asn60 or Asn112 of myc-
hCRLR to Thr revealed less extensive N-glycosylation in the
absence and presence of RAMP1 and -2, but cell surface ex-
pression was largely unchanged. In the double mutant myc-
hCRLR(N60, 112T) the extent of N-glycosylation was further
reduced and cell surface expression was now decreased. As a
result, only minimal speci¢c [125I]CGRP and -ADM binding
was observed. These results were consistent with those ob-
tained in tunicamycin-treated cells where dose-dependent in-
hibition of N-glycosylation also impaired [125I]CGRP and
-ADM binding. Interestingly, mutation of Asn117 to Thr did
not a¡ect N-glycosylation and expression of the receptor at
the cell surface to any great extent, but speci¢c [125I]CGRP
and -ADM binding was obliterated. Apparently, minimal
N-glycosylation of Asn117 in myc-hCRLR(N60, 112T) was
insu⁄cient for its normal delivery to the cell surface. Thus,
Asn117 of myc-hCRLR is required for CGRP or ADM recog-
nition in the presence of RAMP1 or -2, respectively. It is,
however, not required for N-glycosylation and cell surface
delivery of the hCRLR.
The functional role of N-glycosylation of the related hCT
receptors, in particular of the hCTR type 3 with approxi-
mately 60% homology to the CRLR and also three N-termi-
nal N-glycosylation consensus sites has been reported [12].
Much like with the hCRLR, site-directed mutagenesis of the
¢rst consensus site did not a¡ect high-a⁄nity salmon CT
binding. hCT receptors lacking the second or third consensus
site exhibited less potent cAMP production. Correspondingly,
with the myc-hCRLR(N112T) the IC50 of ADM with respect
to [125I]ADM binding was somewhat higher than that of the
myc-hCRLR. In marked contrast, substitution of the Asn117
by Thr inactivated the myc-hCRLR.
In conclusion, hCRLR N-glycosylation at Asn60 and/or
Asn112 is required for cell surface expression and [125I]CGRP
or -ADM binding in the presence of RAMP1 or -2. The myc-
hCRLR(N117T), on the other hand, is delivered to the cell
surface, but the mutated hCRLR is inactive.
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